KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to 0.14.

  • Travere Therapeutics' Equity Ratio rose 32623.18% to 0.14 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.14, marking a year-over-year increase of 32623.18%. This contributed to the annual value of 0.1 for FY2024, which is 6093.53% down from last year.
  • Per Travere Therapeutics' latest filing, its Equity Ratio stood at 0.14 for Q3 2025, which was up 32623.18% from 0.06 recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Equity Ratio peaked at 0.47 during Q1 2021, and registered a low of 0.06 during Q3 2024.
  • Moreover, its 5-year median value for Equity Ratio was 0.16 (2023), whereas its average is 0.2.
  • In the last 5 years, Travere Therapeutics' Equity Ratio tumbled by 11797.35% in 2024 and then surged by 32623.18% in 2025.
  • Quarter analysis of 5 years shows Travere Therapeutics' Equity Ratio stood at 0.39 in 2021, then tumbled by 83.62% to 0.06 in 2022, then soared by 299.52% to 0.25 in 2023, then plummeted by 60.94% to 0.1 in 2024, then skyrocketed by 37.36% to 0.14 in 2025.
  • Its last three reported values are 0.14 in Q3 2025, 0.06 for Q2 2025, and 0.06 during Q1 2025.